Clinigen Group (LON:CLIN) target price held steady at 800.00GBX, issued a report today by N+1 Singer
- Updated: September 27, 2016
Having a price of 712.50GBX, Clinigen Group (LON:CLIN) traded -1.31% lower on the day. With the last stock price up 13.51% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CLIN has recorded a 50-day average of 651.96GBX and a two hundred day average of 596.84GBX. Trade Volume was down over the average, with 228,982 shares of CLIN changing hands under the typical 496,983
Clinigen Group (LON:CLIN) had its stock price target hold steady to 800.00GBX by N+1 Singer in a report issued 9/28/2016. The updated target price indicates a possible upside of 0.12% from the company's most recent stock price.
On Wednesday July 20, 2016, numis released a statement about Clinigen Group (LON:CLIN) upped the target price from 0.00GBX to 916.00GBX that suggested an upside of 0.34%.
Recent Performance Chart
Clinigen Group has with a one year low of 492.75GBX and a one year high of 723.50GBX and has a market capitalization of 0 GBX.
A total of 5 brokerages have issued a ratings update on Clinigen Group. Three brokerages rating the company a strong buy, two brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 850.00GBX.
General Company Details For Clinigen Group (LON:CLIN)
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). The CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. The MA segment specializes in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies. The GA segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these often-essential drugs. The SP segment manufactures and distributes its own and in-license specialist, hospital-only medicines.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.